{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:21:17Z","timestamp":1770819677194,"version":"3.50.1"},"posted":{"date-parts":[[2025,10,11]]},"group-title":"In Review","reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,9,8]]},"abstract":"<title>Abstract<\/title>\n                <p>Background:\nAs the burden of opioid use disorder (OUD) increases in low- and middle-income countries, expanding access to medications for opioid use disorder, including methadone maintenance therapy, is essential. Decentralized models of methadone service delivery aim to improve treatment access, reduce costs for clients and burdens on health systems, and deliver more client-centered care. However, questions remain about the feasibility, acceptability, and implementation of decentralized models for methadone delivery, particularly in Africa. We qualitatively examined client and provider perspectives on decentralized methadone service delivery through satellite community health centers in Tanzania.\nMethods:\nWe conducted a qualitative study with in-depth interviews among 10 providers and four focus groups with 40 participants (clients enrolled in OUD care, outreach workers, and treatment supporters) in Dar es Salaam, Tanzania. Through thematic analysis guided by the Consolidated Framework for Implementation Research (CFIR), we explored the experiences and perceptions of decentralized methadone services, including benefits, barriers, and recommendations.\nResults:\nParticipants described key advantages of decentralization, such as reduced travel time and costs, improved access for clients with family or work obligations, and less congestion at central specialized opioid treatment clinic. However, they reported challenges across CFIR domains. Under intervention characteristics, clients perceived lower quality of care and less monitoring at satellite community health centers than at specialized opioid treatment clinics. Outer setting factors, such as privacy concerns and stigma, were perceived barriers to decentralized methadone delivery. Compared with specialized clinics, community health centers have fewer wrap-around services, reinforcing perceptions of poor quality of care. Individual characteristics, such as the risk of losing peer support networks and fears of drug testing, further discouraged clients from desiring to be transferred to community health centers. Finally, limited client involvement in planning and unclear communications were viewed as factors contributing to mistrust and resistance among clients to receive their methadone treatment at a community health center.\nConclusions:\nAddressing community stigma, ensuring consistent service quality, supporting and enhancing clients\u2019 social connections, and fostering transparent and participatory planning processes will be critical to effectively implement decentralized methadone service delivery.<\/p>","DOI":"10.21203\/rs.3.rs-7565402\/v1","type":"posted-content","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:23:47Z","timestamp":1760145827000},"source":"Crossref","is-referenced-by-count":1,"title":["Implementation Challenges and Opportunities in Decentralized Methadone Service Delivery"],"prefix":"10.21203","author":[{"given":"Iddi Haruna","family":"Nkya","sequence":"first","affiliation":[{"name":"Muhimbili National Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feaven","family":"Gebrezgi","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adela","family":"Luswetula","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessie","family":"Mbwambo","sequence":"additional","affiliation":[{"name":"Muhimbili National Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haneefa T.","family":"Saleem","sequence":"additional","affiliation":[{"name":"Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization Copyright \u00a9 2009, World Health Organization.; 2009."},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13722-023-00374-1","article-title":"Economic, social, and clinic influences on opioid treatment program retention in Dar es Salaam, Tanzania: a qualitative study","volume":"18","author":"Knight D","year":"2023","unstructured":"Knight D, Nkya IH, West NS, Yang C, Kidorf M, Latkin C, et al. Economic, social, and clinic influences on opioid treatment program retention in Dar es Salaam, Tanzania: a qualitative study. Addict Sci Clin Pract. 2023;18(1):19.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13722-024-00468-4","article-title":"Retention of people who inject drugs enrolled in a 'medications for opioid use disorder' (MOUD) programme in Uganda","volume":"19","author":"Mudiope P","year":"2024","unstructured":"Mudiope P, Mutamba BB, Komuhangi L, Nangendo J, Alamo S, Mathers B, et al. Retention of people who inject drugs enrolled in a 'medications for opioid use disorder' (MOUD) programme in Uganda. Addict Sci Clin Pract. 2024;19(1):39.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13722-022-00352-z","article-title":"Exploring the experiences of clients receiving opioid use disorder treatment at a methadone clinic in Kenya: a qualitative study","volume":"17","author":"Kiburi SK","year":"2022","unstructured":"Kiburi SK, Mwangi J, Maina G. Exploring the experiences of clients receiving opioid use disorder treatment at a methadone clinic in Kenya: a qualitative study. Addict Sci Clin Pract. 2022;17(1):71.","journal-title":"Addict Sci Clin Pract"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1080\/10826084.2021.1922450","article-title":"Qualitative Analysis of Community Support to Methadone Access in Kenya","volume":"56","author":"Ndimbii J","year":"2021","unstructured":"Ndimbii J, Guise A, Igonya EK, Owiti F, Strathdee S, Rhodes T. Qualitative Analysis of Community Support to Methadone Access in Kenya. Subst Use Misuse. 2021;56(9):1312\u20139.","journal-title":"Subst Use Misuse"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12954-015-0063-0","article-title":"Preference of methadone maintenance patients for the integrative and decentralized service delivery models in Vietnam","volume":"12","author":"Tran BX","year":"2015","unstructured":"Tran BX, Nguyen LH, Phan HT, Nguyen LK, Latkin CA. Preference of methadone maintenance patients for the integrative and decentralized service delivery models in Vietnam. Harm Reduct J. 2015;12:29.","journal-title":"Harm Reduct J"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/dar.13613","article-title":"Challenges of methadone maintenance treatment decentralisation from Vietnamese primary care providers' perspectives","volume":"42","author":"Nguyen DB","year":"2023","unstructured":"Nguyen DB, Nguyen TT, Lin C, Dinh TTT, Le GM, Li L. Challenges of methadone maintenance treatment decentralisation from Vietnamese primary care providers' perspectives. Drug Alcohol Rev. 2023;42(4):803\u201314.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"ref8","article-title":"[Ensuring continuity of care at the time of COVID-19: challenges for the Dakar Integrated Support Center for Addictions]","volume":"1","author":"Ba I","year":"2021","unstructured":"Ba I, Desclaux A, Diop M, Ndiaye I, Thiam MH. [Ensuring continuity of care at the time of COVID-19: challenges for the Dakar Integrated Support Center for Addictions]. Med Trop Sante Int. 2021;1(1).","journal-title":"Med Trop Sante Int"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","article-title":"Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact","volume":"11","author":"Brooklyn JR","year":"2017","unstructured":"Brooklyn JR, Sigmon SC. Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact. J Addict Med. 2017;11(4):286\u201392.","journal-title":"J Addict Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jsat.2019.07.007","article-title":"The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders","volume":"108","author":"Reif S","year":"2020","unstructured":"Reif S, Brolin MF, Stewart MT, Fuchs TJ, Speaker E, Mazel SB. The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders. J Subst Abuse Treat. 2020;108:33\u20139.","journal-title":"J Subst Abuse Treat"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jsat.2019.05.005","article-title":"West Virginia's model of buprenorphine expansion: Preliminary results","volume":"108","author":"Winstanley EL","year":"2020","unstructured":"Winstanley EL, Lander LR, Berry JH, Mahoney JJ 3rd, Zheng W, Herschler J, et al. West Virginia's model of buprenorphine expansion: Preliminary results. J Subst Abuse Treat. 2020;108:40\u20137.","journal-title":"J Subst Abuse Treat"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2018.04.029","article-title":"Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies","volume":"191","author":"Gauthier G","year":"2018","unstructured":"Gauthier G, Eibl JK, Marsh DC. Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies. Drug Alcohol Depend. 2018;191:1\u20135.","journal-title":"Drug Alcohol Depend"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"104487","DOI":"10.1016\/j.drugpo.2024.104487","article-title":"Comparing methadone policy and practice in France and the US: Implications for US policy reform","volume":"129","author":"Englander H","year":"2024","unstructured":"Englander H, Chappuy M, Krawczyck N, Bratberg J, Potee R, Jauffret-Roustide M, et al. Comparing methadone policy and practice in France and the US: Implications for US policy reform. Int J Drug Policy. 2024;129:104487.","journal-title":"Int J Drug Policy"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"209086","DOI":"10.1016\/j.josat.2023.209086","article-title":"Changes to methadone maintenance therapy in the United States, Canada, and Australia during the COVID-19 pandemic: A narrative review","volume":"152","author":"Panwala V","year":"2023","unstructured":"Panwala V, Joudrey P, Kowalski M, Bach P, Amram O. Changes to methadone maintenance therapy in the United States, Canada, and Australia during the COVID-19 pandemic: A narrative review. J Subst Use Addict Treat. 2023;152:209086.","journal-title":"J Subst Use Addict Treat"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s11096-019-00790-x","article-title":"Community pharmacists' role in preventing opioid substitution therapy-related deaths: a qualitative investigation into current UK practice","volume":"41","author":"Yadav R","year":"2019","unstructured":"Yadav R, Taylor D, Taylor G, Scott J. Community pharmacists' role in preventing opioid substitution therapy-related deaths: a qualitative investigation into current UK practice. Int J Clin Pharm. 2019;41(2):470\u20137.","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4066\/AMJ.2011.706","article-title":"Provision of opioid substitution therapy services in Australian pharmacies","volume":"4","author":"Chaar BB","year":"2011","unstructured":"Chaar BB, Hanrahan JR, Day C. Provision of opioid substitution therapy services in Australian pharmacies. Australas Med J. 2011;4(4):210\u20136.","journal-title":"Australas Med J"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.4102\/phcfm.v14i1.3386","article-title":"Managing acute opioid withdrawal with tramadol during COVID-19 lockdown in a peri-urban setting","volume":"14","author":"Bhoora U","year":"2022","unstructured":"Bhoora U, Gloeck NR, Scheibe A. Managing acute opioid withdrawal with tramadol during COVID-19 lockdown in a peri-urban setting. Afr J Prim Health Care Fam Med. 2022;14(1):e1\u20139.","journal-title":"Afr J Prim Health Care Fam Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-319-63522-4_3","volume-title":"Structural Dynamics of HIV. Social Aspects of HIV","author":"Mbwambo J","year":"2018","unstructured":"Mbwambo J, Saleem HT, Kaduri P, Lambdin B, McCurdy S. Addressing the micro- and macro-environmental vulnerabilities to HIV of people who inject drugs in Tanzania: A case study of the Muhimbili medication-assisted treatment clinic. In: Kerrigan D, Barrington C, editors. Structural Dynamics of HIV. Social Aspects of HIV. 1 ed. Cham, Switzerland: Springer International Publishing; 2018. pp. 45\u201363.","edition":"1"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/09540121.2022.2032575","article-title":"HIV status disclosure, and ART adherence in the context of an integrated opioid use disorder and HIV treatment setting in Dar es Salaam, Tanzania","volume":"35","author":"Saleem HT","year":"2023","unstructured":"Saleem HT, Knight D, Yang C, Kidorf M, Latkin C, Nkya IH, HIV, Stigma. HIV status disclosure, and ART adherence in the context of an integrated opioid use disorder and HIV treatment setting in Dar es Salaam, Tanzania. AIDS Care. 2023;35(1):91\u20134.","journal-title":"AIDS Care"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13012-022-01245-0","article-title":"The updated Consolidated Framework for Implementation Research based on user feedback","volume":"17","author":"Damschroder LJ","year":"2022","unstructured":"Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated Consolidated Framework for Implementation Research based on user feedback. Implement Sci. 2022;17(1):75.","journal-title":"Implement Sci"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"107968","DOI":"10.1016\/j.drugalcdep.2020.107968","article-title":"Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study","volume":"211","author":"Joudrey PJ","year":"2020","unstructured":"Joudrey PJ, Chadi N, Roy P, Morford KL, Bach P, Kimmel S, et al. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study. Drug Alcohol Depend. 2020;211:107968.","journal-title":"Drug Alcohol Depend"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"100067","DOI":"10.1016\/j.dadr.2022.100067","article-title":"Opioid treatment program prescribing of methadone with community pharmacy dispensing: Pilot study of feasibility and acceptability","volume":"3","author":"Brooner RK","year":"2022","unstructured":"Brooner RK, Stoller KB, Patel P, Wu L-T, Yan H, Kidorf M. Opioid treatment program prescribing of methadone with community pharmacy dispensing: Pilot study of feasibility and acceptability. Drug Alcohol Depend Rep. 2022;3:100067.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13722-023-00399-6","article-title":"Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S","volume":"18","author":"Wu L-T","year":"2023","unstructured":"Wu L-T, John WS, Mannelli P, Morse ED, Anderson A, Schwartz RP. Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S. Addict Sci Clin Pract. 2023;18(1):45.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12875-018-0792-8","article-title":"Optimising treatment in opioid dependency in primary care: results from a national key stakeholder and expert focus group in Ireland","volume":"19","author":"Hout MC","year":"2018","unstructured":"Van Hout MC, Crowley D, McBride A, Delargy I. Optimising treatment in opioid dependency in primary care: results from a national key stakeholder and expert focus group in Ireland. BMC Fam Pract. 2018;19(1):103.","journal-title":"BMC Fam Pract"},{"issue":"1","key":"ref25","first-page":"e1","article-title":"Retention of service users on opioid substitution therapy in the City of Tshwane, South Africa","volume":"15","author":"Goeieman DS","year":"2023","unstructured":"Goeieman DS, Nonyane DS, Nzaumvila DK, van Anse MNS. Retention of service users on opioid substitution therapy in the City of Tshwane, South Africa. Afr J Prim Health Care Fam Med. 2023;15(1):e1\u201310.","journal-title":"Afr J Prim Health Care Fam Med"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12954-020-00368-1","article-title":"High retention in an opioid agonist therapy project in Durban, South Africa: the role of best practice and social cohesion","volume":"17","author":"Marks M","year":"2020","unstructured":"Marks M, Scheibe A, Shelly S. High retention in an opioid agonist therapy project in Durban, South Africa: the role of best practice and social cohesion. Harm Reduct J. 2020;17(1):25.","journal-title":"Harm Reduct J"},{"key":"ref27","first-page":"11782218211039781","article-title":"Barriers for Implementing the Hub and Spoke Model to Expand Medication for Opioid Use Disorder: A Case Study of Montana","volume":"15","author":"Green B","year":"2021","unstructured":"Green B, Rhubart DC, Filteau MR. Barriers for Implementing the Hub and Spoke Model to Expand Medication for Opioid Use Disorder: A Case Study of Montana. Subst Abuse: Res Treat. 2021;15:11782218211039781.","journal-title":"Subst Abuse: Res Treat"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12884-023-06172-6","article-title":"Scoping review: mapping clinical guidelines and policy documents that address the needs of women who are dependent on drugs during the perinatal period","volume":"24","author":"Gilmour L","year":"2024","unstructured":"Gilmour L, Honeybul L, Lewis S, Smith E, Cheyne H, Aladangady N, et al. Scoping review: mapping clinical guidelines and policy documents that address the needs of women who are dependent on drugs during the perinatal period. BMC Pregnancy Childbirth. 2024;24(1):84.","journal-title":"BMC Pregnancy Childbirth"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7565402\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7565402\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:18:09Z","timestamp":1765815489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7565402\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":28,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-7565402\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s12913-025-13813-3","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,10,11]]},"subtype":"preprint"}}